Intec Pharma Ltd

Intec Pharma — Investor Presentation (March 2017)

35 slides from Intec Pharma's investor presentation, Mar 23, 2017

  1. Slide 1: Corporate Presentation: Unfolding drug delivery solutions

    Corporate Presentation Nasdaq/TASE: NTEC March 2017 Unfolding drug delivery solutions

  2. Slide 2: Forward Looking Statements

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 2 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as “we” or “our”) contains forward - looking statements about our expectations , beliefs and intentions regarding, a

  3. Slide 3: Table of Contents

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 3 Table of Contents 1. Executive Summary 2. AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need 3. AP - CD/LD for Parkinson’s Disease: Clinical Development 4. AP - CBD/THC Ca

  4. Slide 4: 1. Executive Summary

    INTEC PHARMA 1. Executive Summary

  5. Slide 5: Experienced Management Team

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 5 Zeev Weiss, BSc, CPA Chief Executive Officer  Former Head of Life Sciences Strategic Consulting, PwC Israel  More than 15 years of experience in healthcare corporate development and strategic p

  6. Slide 6: Executive Summary

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 6 Executive Summary  A Late - stage drug development company utilizing a proprietary oral drug delivery system – the Accordion Pill TM (AP) • The Accordion Pill, currently in clinical testing, is

  7. Slide 7: Accordion Pill Platform Technology

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 7 Executive Summary  Combines drugs and inactive ingredients into multiple polymeric films that are layered into a planar structure, folded into t he shape of an accordion and placed inside a stan

  8. Slide 8: Our Unique Accordion Pill Drug Delivery Process

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 8 Executive Summary Our Unique Accordion Pill Drug Delivery Process AP movie.wmv

  9. Slide 9: Drugs Particularly Suited to the Accordion Pill Platform

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 9 Executive Summary  Narrow Absorption Window: drug absorption is confined mainly to the upper part of the GI tract, with poor colonic absorption  Low solubility. For poorly soluble drugs , the A

  10. Slide 10: Product Pipeline

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 10 Executive Summary Product Pipeline ( 1 ) Developed under 505 (b)( 2 ). Intec Pipeline Product Candidate Research Phase I Phase II Phase III Next Steps AP - CD/LD (1) Parkinson's disease symptoms

  11. Slide 11: Recent/Upcoming Milestones

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 11 Executive Summary Recent/Upcoming Milestones Q 1 : 2016 Q2:2016 Q 3 : 2016 Q 4 : 2016 Q 1 : 2017 Q 3 : 2017 Q 2 : 2017 Q 4 : 2017 Q 2 : 2016 : Enrolled first patient in pivotal Phase III clinica

  12. Slide 12: Capital Structure, Cash and Institutional Holders

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 12 Executive Summary $ $ 21.4 M in cash and short term bank deposits and financial assets as of June 30 , 2016 $5.2M Approved grant from the Israeli National Authority for Technological Innovation

  13. Slide 13: 2. AP-CD/LD for Parkinson's Disease: Unmet Medical Need

    2 . AP - CD/LD for Parkinson’s Disease : Our Approach for an Unmet Medical Need

  14. Slide 14: Parkinson's Disease Market Overview

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 14 AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need  The second most common neurodegenerative disorder in elderly, affecting 1% – 2% of individuals ages ≥65 years worldwi

  15. Slide 15: Limited Success of Current Levodopa Delivery Efforts

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 15 AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need Current efforts to provide stable, therapeutic levodopa levels, with easy - to - use delivery, have had limited success

  16. Slide 16: AP-CD/LD New Paradigm Product Concept

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 16 AP - CD/LD for Parkinson’s Disease: Our Approach for an Unmet Medical Need AP - CD/LD introduces a new approach: AP - CD/LD New Paradigm Product Concept: BID or TID administration of AP - CD/LD

  17. Slide 17: 3. AP-CD/LD for Parkinson's Disease: Clinical Development

    3 . AP - CD/LD for Parkinson’s Disease: Clinical Development

  18. Slide 18: Clinical Steering and Enrollment Committees

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 18 Warren Olanow , MD Karl Kieburtz, MD, MPH AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Clinical Steering and Enrollment Committees Peter A. LeWitt , MD Robert Hauser, MD,

  19. Slide 19: AP-CD/LD Phase II Trial Structure

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 19 AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Phase II Trial Structure (a) Eight patients completed the PK trial. (b) Group 5 was terminated early due to low enrollment. d

  20. Slide 20: Phase II Advanced Patients, Multi-dose PK

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 20 AP - CD/LD for Parkinson’s Disease: Clinical Development Phase II, Advanced Patients , Multi - dose PK (Group 3 ) Trial Design Screening Randomization 6 days Day 7 6 days Day 7 PK PK AP - CDLD 5

  21. Slide 21: Phase II Advanced Patients, 21 Days Treatment Trial Design

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 21 AP - CD/LD for Parkinson’s Disease: Clinical Development Significantly Reduced TSD Significantly Reduced OFF Time Screening Randomization 17 days conversion 4 days 17 days optimization 4 days te

  22. Slide 22: AP-CD/LD Phase III Accordance Trial Design

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 22 AP - CD/LD for Parkinson’s Disease: Clinical Development  Design: • Multi - center, global, randomized, double - blind, double - dummy, active - controlled, parallel - group study in adult pati

  23. Slide 23: AP-CD/LD Phase III Trial Design

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 23 AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Phase III Trial Design 4 Weeks 6 Weeks 13 Weeks 2 Weeks With reference drug = Sinemet 50 / 400 , 50 / 500 BID, TID Open label

  24. Slide 24: AP-CD/LD Development Timeline

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 24 AP - CD/LD for Parkinson’s Disease: Clinical Development AP - CD/LD Development Timeline AP - CD/LD Trial Status 2016 2017 2018 2019  Q2:2016: First patient enrolled in Phase III trial  Q4:201

  25. Slide 25: 4. AP-CBD/THC Cannabinoid Therapy

    4 . AP - CBD/THC Cannabinoid Therapy

  26. Slide 26: AP-CBD/THC Cannabinoid Therapy

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 26 Market Opportunity Intec’s Solution Under Development AP - CBD/THC Cannabinoid Therapy AP - CBD/THC Cannabinoid Therapy ( 1 ) Source: Viridian Capital Advisors. ( 2015 , December 2 ). REPORT: Th

  27. Slide 27: 5. AP-Zaleplon (ZP) for Insomnia

    5 . AP - Zaleplon (ZP) for Insomnia

  28. Slide 28: AP-ZP for Insomnia

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 28 AP - ZP for Insomnia  In 2013 , there were approximately 140 MM prevalent cases of chronic insomnia in the Seven Major Markets ( 1 )( 2 )( 3 )  The sleep disorder drug market in these markets

  29. Slide 29: AP-ZP for Insomnia

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 29 AP - ZP for Insomnia  AP - ZP contains Zaleplon (generic Sonata) in both immediate and controlled release forms  Zaleplon is approved for sleep induction. Its short half life (~ 1 hour) result

  30. Slide 30: 6. AP Platform for Poorly Soluble Drugs

    7 . AP Platform for Poorly Soluble Drugs

  31. Slide 31: AP Platform for Poorly Soluble Drugs

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 31 AP Platform for Poorly Soluble Drugs  The AP platform technology is also designed for drugs with low solubility, namely Biopharmaceutics Classification System, or BCS , Class II (low solubility

  32. Slide 32: Accordion Pill with Poorly Soluble Drugs: PK Clinical Study

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 32 AP Platform for Poorly Soluble Drugs  PK issues of drug X include only 30 % absorption and lack of dose proportionality above an approved marketed dose ( Xmg )  AP significantly extended the a

  33. Slide 33: 7. IP Overview

    INTEC PHARMA 7. IP Overvie

  34. Slide 34: Three Layers of IP Protection

    13 117 156 11 104 139 17 154 206 155 205 238 194 225 245 86 167 100 142 179 14 240 240 240 105 105 105 34 IP Overview  Platform IP • Various Accordion Pill dosage forms • Latest US patent expires in 2029  Manufacturing IP • Methods for making/folding gastroretentive drug delivery system • US paten

  35. Slide 35: Thank You

    THANK YOU INTEC PHARMA LTD. 12 Hartom st. (RMPE building) P.O. Box 45219 Jerusalem 9777512 Israel Tel: + 972 - 2 - 5864657 Fax: + 972 - 2 - 5869176 [email protected]

Intec Pharma — Investor Presentation (March 2017) on 6ix